Literature DB >> 9087680

Physiological role of nitric oxide in regulation of renal function in humans.

W G Haynes1, M F Hand, M E Dockrell, D W Eadington, M R Lee, Z Hussein, N Benjamin, D J Webb.   

Abstract

The physiological role of endogenous nitric oxide in regulation of renal function in humans is unclear. Eight healthy men received an inhibitor of nitric oxide synthase, N(G)-monomethyl-L-arginine (L-NMMA, 3 mg/kg), and saline placebo intravenously on two occasions. L-NMMA significantly increased mean arterial pressure (+7%) and total peripheral resistance (+36%). However, because renal plasma flow did not decrease significantly, the increase in renal vascular resistance (+21%) was significantly less than the increase in total peripheral resistance. Glomerular filtration rate (-19%), filtration fraction (-10%), urine flow rate (-18%), sodium (-28%), and free water excretion (-25%) all decreased significantly. Fractional distal, but not proximal, sodium reabsorption increased. L-NMMA also significantly decreased plasma nitrate and urinary excretion of nitrate and dopamine. There were no significant changes in plasma renin activity, plasma endothelin, and aldosterone or in platelet number and ex vivo aggregation. L-NMMA had a plasma half-life of 75 min. Basal generation of nitric oxide appears to contribute less to vascular tone in the kidney than systemically but may alter afferent arteriolar tone. Decreased fractional sodium excretion supports an important physiological role for nitric oxide in inhibition of tubular sodium reabsorption, possibly mediated by the renal dopaminergic system.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9087680     DOI: 10.1152/ajprenal.1997.272.3.F364

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

Review 1.  Endothelial nitric oxide in humans in health and disease.

Authors:  P Vallance; A Hingorani
Journal:  Int J Exp Pathol       Date:  1999-12       Impact factor: 1.925

2.  Urinary nitrite excretion and urinary variables in patients with primary nocturnal frequency of micturition: effects of indomethacin suppositories.

Authors:  Noori S Al-Waili; Thia N Al-Waili; Ali N Al-Waili; Khelod Y Saloom
Journal:  World J Urol       Date:  2005-09-27       Impact factor: 4.226

Review 3.  Dopamine receptor-coupling defect in hypertension.

Authors:  Pedro A Jose; Gilbert M Eisner; Robin A Felder
Journal:  Curr Hypertens Rep       Date:  2002-06       Impact factor: 5.369

4.  Pharmacokinetic-pharmacodynamic profile of systemic nitric oxide-synthase inhibition with L-NMMA in humans.

Authors:  B X Mayer; C Mensik; S Krishnaswami; H Derendorf; H G Eichler; L Schmetterer; M Wolzt
Journal:  Br J Clin Pharmacol       Date:  1999-05       Impact factor: 4.335

Review 5.  Endothelial nitric oxide synthase polymorphisms and hypertension.

Authors:  Aroon D Hingorani
Journal:  Curr Hypertens Rep       Date:  2003-02       Impact factor: 5.369

Review 6.  Selective iNOS inhibition for the treatment of sepsis-induced acute kidney injury.

Authors:  Suzanne Heemskerk; Rosalinde Masereeuw; Frans G M Russel; Peter Pickkers
Journal:  Nat Rev Nephrol       Date:  2009-09-29       Impact factor: 28.314

7.  Mechanisms of acute natriuresis in normal humans on low sodium diet.

Authors:  M S Rasmussen; J A Simonsen; N C F Sandgaard; P F Høilund-Carlsen; P Bie
Journal:  J Physiol       Date:  2003-01-15       Impact factor: 5.182

8.  Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-beta, and nitrite excretion.

Authors:  Liora Adler; Roy Mathew; Stephen Futterweit; Rachel Frank; Bernard G Gauthier; Clifford E Kashtan; Howard Trachtman
Journal:  BMC Nephrol       Date:  2002-02-14       Impact factor: 2.388

9.  Effects of Inhibition of Nitric Oxide Synthase on Muscular Arteries During Exercise: Nitric Oxide Does Not Contribute to Vasodilation During Exercise or in Recovery.

Authors:  Kevin O'Gallagher; Husain Shabeeh; Shahzad Munir; Ali Roomi; Benyu Jiang; Antoine Guilcher; Sally Brett; Philip Chowienczyk
Journal:  J Am Heart Assoc       Date:  2020-08-12       Impact factor: 5.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.